PriceTargets.com logo

OS Therapies - OSTX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 69.85%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 2 Strong Buy Ratings
$4.71 As of 12/17/2024 01:00 AM ET
▲ +1.23 (35.34%)

This chart shows the closing price for OSTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OS Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSTX

Analyst Price Target is $8.00
▲ +69.85% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OS Therapies in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 69.85% upside from the last price of $4.71.

This chart shows the closing price for OSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 3 polled investment analysts is to buy (strong buy) stock in OS Therapies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 2 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 2 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/26/2024Maxim GroupInitiated CoverageBuy$8.00
9/3/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/22/2024Brookline Capital ManagementUpgradeStrong-Buy
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
OS Therapies logo
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Read More

Today's Range

Now: $4.71
Low: $3.26
High: $6.48

50 Day Range

MA: $2.64
Low: $1.74
High: $4.71

52 Week Range

Now: $4.71
Low: $1.58
High: $6.48

Volume

668,717 shs

Average Volume

131,554 shs

Market Capitalization

$100.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OS Therapies?

The following Wall Street sell-side analysts have issued research reports on OS Therapies in the last twelve months: Brookline Capital Management, EF Hutton Acquisition Co. I, and Maxim Group.
View the latest analyst ratings for OSTX.

What is the current price target for OS Therapies?

0 Wall Street analysts have set twelve-month price targets for OS Therapies in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 69.9%. Maxim Group has the highest price target set, predicting OSTX will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $8.00 for OS Therapies in the next year.
View the latest price targets for OSTX.

What is the current consensus analyst rating for OS Therapies?

OS Therapies currently has 1 buy rating and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for OSTX.

What other companies compete with OS Therapies?

Other companies that are similar to OS Therapies include Foghorn Therapeutics, Atea Pharmaceuticals, Eledon Pharmaceuticals, UroGen Pharma and Rezolute. Learn More about companies similar to OS Therapies.

How do I contact OS Therapies' investor relations team?

OS Therapies' physical mailing address is 15825 SHADY GROVE ROAD, SUITE 135, ROCKVILLE, MD, 20850. The company's listed phone number is (410) 297-7793 and its investor relations email address is [email protected]. The official website for OS Therapies is ostherapies.com. Learn More about contacing OS Therapies investor relations.